SAB Biotherapeutics, Inc.
NASDAQ:SABSBiotechnology
Healthcare
$2.91 -0.53%
-$0.02 today
- Market cap
- $262.16M
- Beta
- 0.53
- P/E (TTM)
- 3.0
- EPS (TTM)
- -$0.16
52W Low $1.85High $5.15
Volume 1.75M
Average 0.76M
Balance Sheet
Inspect the capital base behind the business.
Assets
$172.81M
FY 2025 · Annual
+291.0% YoYLiabilities
$21.32M
FY 2025 · Annual
+17.0% YoYEquity
$151.49M
FY 2025 · Annual
+483.4% YoYBalance Sheet
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 33.21M | 15.05M | 56.57M | 8.9M | 10.5M |
| Short-term Investments | 0 | 0 | 0 | 11.86M | 86.09M |
| Net Receivables | 8.01M | 5.56M | 0 | 54.96K | 946.78K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 6.34M | 0 | 0 | 2.98M | 3.51M |
| Total Current Assets | 50.19M | 22.1M | 58.91M | 23.79M | 101.05M |
| Property, Plant & Equipment (Net) | 30.95M | 28.34M | 24.68M | 19.92M | 19.4M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 46.89M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | (1) | 467.69K | 350.23K | 482.1K | 5.46M |
| Total Non-current Assets | 30.95M | 28.81M | 25.03M | 20.4M | 71.76M |
| Total Assets | 81.14M | 50.9M | 83.94M | 44.2M | 172.81M |
| Account Payables | 4.46M | 3.68M | 945.93K | 1.69M | 3.15M |
| Short-term Debt | 1.8M | 772.67K | 1.05M | 275.85K | 951.37K |
| Tax Payables | 216.25K | 50K | 40K | 0 | 0 |
| Deferred Revenue | 100K | 0 | 1.32M | 0 | 0 |
| Other Current Liabilities | 8.7M | 8.1M | 4.49M | 0 | 1.55M |
| Total Current Liabilities | 26.46M | 14.99M | 10.81M | 7.98M | 10.68M |
| Long-term Debt | 0 | 541.64K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 10.72M | 320.93K | 11.77M | 6.39M | 5.64M |
| Total Non-current Liabilities | 16.14M | 4.85M | 15.83M | 10.25M | 10.63M |
| Total Liabilities | 42.59M | 19.85M | 26.64M | 18.23M | 21.32M |
| Common Stock | 4.35K | 5.09K | 929 | 935 | 4.77K |
| Retained Earnings | (29.13M) | (47.87M) | (90.06M) | (124.17M) | (110.9M) |
| Accumulated OCI | 0 | 0 | 26.42K | (135.41K) | 186.51K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 38.55M | 31.06M | 57.3M | 25.97M | 151.49M |
| Total Debt | 8.52M | 5.93M | 5.91M | 4.67M | 5.95M |
| Net Debt | (24.69M) | (9.12M) | (50.66M) | (4.23M) | (4.55M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $8.3M |
| Short-term Investments | $94.4M |
| Receivables | $1.8M |
| Other Current | $3.5M |
| Total Current Assets | $107.9M |
| PP&E (Net) | $19.6M |
| Long-term Investments | $105.3M |
| Other Non-current | $5.3M |
| Total Non-current Assets | $130.3M |
| Total Assets | $238.2M |
Analysis
Selected assets total $238.2M for Latest. The largest visible component is Long-term Investments at $105.3M, about 44.2% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 25-NSE | 25-NSE filing | Oct 22, 2026 | |
| 8-K | Current report | Oct 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 18, 2026 | |
| 424B3 | 424B3 filing | Aug 21, 2026 |
How much cash does SABS have?
SAB Biotherapeutics, Inc. (SABS) reported $10.50M in cash and equivalents in fiscal 2025.
How much debt does SABS carry?
SAB Biotherapeutics, Inc. (SABS) reported $5.95M of total debt, with net debt of -$4.55M.
Continue the stock analysis
Jump to another research area for this company.